Do analysts prefer BMGL or MGRX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Basel Medical Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Mangoceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, BMGL or MGRX?

Basel Medical Group has higher revenue and earnings than Mangoceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Basel Medical Group $8.90M 0.94 -$9.50M N/A N/A Mangoceuticals $460K 19.95 -$20.64M -$1.49 N/A

Does the media favor BMGL or MGRX?

In the previous week, Mangoceuticals had 1 more articles in the media than Basel Medical Group. MarketBeat recorded 5 mentions for Mangoceuticals and 4 mentions for Basel Medical Group. Basel Medical Group's average media sentiment score of 0.89 beat Mangoceuticals' score of 0.23 indicating that Basel Medical Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Basel Medical Group 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mangoceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend GXAI or BMGL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gaxos.ai 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Basel Medical Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, GXAI or BMGL?

Gaxos.ai has higher earnings, but lower revenue than Basel Medical Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Gaxos.ai $3.72M 1.59 -$3.90M -$0.50 N/A Basel Medical Group $8.90M 0.94 -$9.50M N/A N/A

Does the media refer more to GXAI or BMGL?

In the previous week, Gaxos.ai had 7 more articles in the media than Basel Medical Group. MarketBeat recorded 11 mentions for Gaxos.ai and 4 mentions for Basel Medical Group. Gaxos.ai's average media sentiment score of 0.95 beat Basel Medical Group's score of 0.89 indicating that Gaxos.ai is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gaxos.ai 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Basel Medical Group 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend AIDX or BMGL?

20/20 Biolabs presently has a consensus target price of $5.00, indicating a potential upside of 810.75%. Given 20/20 Biolabs' stronger consensus rating and higher possible upside, equities research analysts clearly believe 20/20 Biolabs is more favorable than Basel Medical Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 20/20 Biolabs 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Basel Medical Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, AIDX or BMGL?

20/20 Biolabs has higher earnings, but lower revenue than Basel Medical Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio 20/20 Biolabs $1.84M 3.65 -$3.74M -$0.28 N/A Basel Medical Group $8.90M 0.94 -$9.50M N/A N/A

Is AIDX or BMGL more profitable?

Company Net Margins Return on Equity Return on Assets 20/20 Biolabs N/A N/A N/A Basel Medical Group N/A N/A N/A

Do analysts recommend IVF or BMGL?

INVO Fertility currently has a consensus price target of $20.00, indicating a potential upside of 1,958.46%. Given INVO Fertility's stronger consensus rating and higher probable upside, research analysts plainly believe INVO Fertility is more favorable than Basel Medical Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score INVO Fertility 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Basel Medical Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, IVF or BMGL?

Basel Medical Group has higher revenue and earnings than INVO Fertility. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio INVO Fertility $7.22M 0.31 -$25.13M -$352.18 N/A Basel Medical Group $8.90M 0.94 -$9.50M N/A N/A

Do analysts rate NIVF or BMGL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NewGenIvf Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Basel Medical Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, NIVF or BMGL?

NewGenIvf Group has higher earnings, but lower revenue than Basel Medical Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NewGenIvf Group $4.73M 0.73 $9.88M N/A N/A Basel Medical Group $8.90M 0.94 -$9.50M N/A N/A

Is NIVF or BMGL more profitable?

Company Net Margins Return on Equity Return on Assets NewGenIvf Group N/A N/A N/A Basel Medical Group N/A N/A N/A

Basel Medical Group (BMGL) Competitors

$5.38 +0.76 (+16.45%)

Closing price 08/14/2026 03:58 PM Eastern

Extended Trading

$5.22 -0.17 (-3.07%)

As of 08/14/2026 07:24 PM Eastern

Compare

BMGL vs. MGRX, GXAI, AIDX, IVF, and NIVF

Should you buy Basel Medical Group stock or one of its competitors? Basel Medical Group's main competitors and comparable companies include Mangoceuticals (MGRX), Gaxos.ai (GXAI), 20/20 Biolabs (AIDX), INVO Fertility (IVF), and NewGenIvf Group (NIVF). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does Basel Medical Group compare to Mangoceuticals?

Basel Medical Group (NASDAQ:BMGL) and Mangoceuticals (NASDAQ:MGRX) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations, valuation and media sentiment.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Basel Medical Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mangoceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Basel Medical Group has a beta of 0.24, indicating that its share price is 76% less volatile than the broader market. Comparatively, Mangoceuticals has a beta of 2.1, indicating that its share price is 110% more volatile than the broader market.

Basel Medical Group has higher revenue and earnings than Mangoceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Basel Medical Group	$8.90M	0.94	-$9.50M	N/A	N/A
Mangoceuticals	$460K	19.95	-$20.64M	-$1.49	N/A

In the previous week, Mangoceuticals had 1 more articles in the media than Basel Medical Group. MarketBeat recorded 5 mentions for Mangoceuticals and 4 mentions for Basel Medical Group. Basel Medical Group's average media sentiment score of 0.89 beat Mangoceuticals' score of 0.23 indicating that Basel Medical Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Basel Medical Group	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mangoceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Basel Medical Group has a net margin of 0.00% compared to Mangoceuticals' net margin of -4,794.60%. Basel Medical Group's return on equity of 0.00% beat Mangoceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Basel Medical Group	N/A	N/A	N/A
Mangoceuticals	-4,794.60%	-92.68%	-87.43%

56.7% of Mangoceuticals shares are owned by institutional investors. 16.0% of Mangoceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Basel Medical Group beats Mangoceuticals on 6 of the 11 factors compared between the two stocks.

How does Basel Medical Group compare to Gaxos.ai?

Gaxos.ai (NASDAQ:GXAI) and Basel Medical Group (NASDAQ:BMGL) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, media sentiment, analyst recommendations and earnings.

In the previous week, Gaxos.ai had 7 more articles in the media than Basel Medical Group. MarketBeat recorded 11 mentions for Gaxos.ai and 4 mentions for Basel Medical Group. Gaxos.ai's average media sentiment score of 0.95 beat Basel Medical Group's score of 0.89 indicating that Gaxos.ai is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gaxos.ai	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Basel Medical Group	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

42.6% of Gaxos.ai shares are held by institutional investors. 3.2% of Gaxos.ai shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Basel Medical Group has a net margin of 0.00% compared to Gaxos.ai's net margin of -64.81%. Basel Medical Group's return on equity of 0.00% beat Gaxos.ai's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gaxos.ai	-64.81%	-38.79%	-36.99%
Basel Medical Group	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gaxos.ai	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Basel Medical Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Gaxos.ai has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market. Comparatively, Basel Medical Group has a beta of 0.24, indicating that its share price is 76% less volatile than the broader market.

Gaxos.ai has higher earnings, but lower revenue than Basel Medical Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gaxos.ai	$3.72M	1.59	-$3.90M	-$0.50	N/A
Basel Medical Group	$8.90M	0.94	-$9.50M	N/A	N/A

Summary

Gaxos.ai beats Basel Medical Group on 7 of the 11 factors compared between the two stocks.

How does Basel Medical Group compare to 20/20 Biolabs?

20/20 Biolabs (NASDAQ:AIDX) and Basel Medical Group (NASDAQ:BMGL) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk.

20/20 Biolabs presently has a consensus target price of $5.00, indicating a potential upside of 810.75%. Given 20/20 Biolabs' stronger consensus rating and higher possible upside, equities research analysts clearly believe 20/20 Biolabs is more favorable than Basel Medical Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
20/20 Biolabs	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Basel Medical Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Basel Medical Group had 1 more articles in the media than 20/20 Biolabs. MarketBeat recorded 4 mentions for Basel Medical Group and 3 mentions for 20/20 Biolabs. 20/20 Biolabs' average media sentiment score of 1.43 beat Basel Medical Group's score of 0.89 indicating that 20/20 Biolabs is being referred to more favorably in the media.

Company	Overall Sentiment
20/20 Biolabs	Positive
Basel Medical Group	Positive

20/20 Biolabs has higher earnings, but lower revenue than Basel Medical Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
20/20 Biolabs	$1.84M	3.65	-$3.74M	-$0.28	N/A
Basel Medical Group	$8.90M	0.94	-$9.50M	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
20/20 Biolabs	N/A	N/A	N/A
Basel Medical Group	N/A	N/A	N/A

Summary

20/20 Biolabs beats Basel Medical Group on 6 of the 8 factors compared between the two stocks.

How does Basel Medical Group compare to INVO Fertility?

INVO Fertility (NASDAQ:IVF) and Basel Medical Group (NASDAQ:BMGL) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk and earnings.

INVO Fertility has a beta of 2.32, meaning that its stock price is 132% more volatile than the broader market. Comparatively, Basel Medical Group has a beta of 0.24, meaning that its stock price is 76% less volatile than the broader market.

Basel Medical Group has higher revenue and earnings than INVO Fertility.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INVO Fertility	$7.22M	0.31	-$25.13M	-$352.18	N/A
Basel Medical Group	$8.90M	0.94	-$9.50M	N/A	N/A

In the previous week, Basel Medical Group had 2 more articles in the media than INVO Fertility. MarketBeat recorded 4 mentions for Basel Medical Group and 2 mentions for INVO Fertility. INVO Fertility's average media sentiment score of 1.87 beat Basel Medical Group's score of 0.89 indicating that INVO Fertility is being referred to more favorably in the media.

Company	Overall Sentiment
INVO Fertility	Very Positive
Basel Medical Group	Positive

INVO Fertility currently has a consensus price target of $20.00, indicating a potential upside of 1,958.46%. Given INVO Fertility's stronger consensus rating and higher probable upside, research analysts plainly believe INVO Fertility is more favorable than Basel Medical Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INVO Fertility	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Basel Medical Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

12.0% of INVO Fertility shares are held by institutional investors. 0.4% of INVO Fertility shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Basel Medical Group has a net margin of 0.00% compared to INVO Fertility's net margin of -183.75%. Basel Medical Group's return on equity of 0.00% beat INVO Fertility's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
INVO Fertility	-183.75%	-420.62%	-45.21%
Basel Medical Group	N/A	N/A	N/A

Summary

INVO Fertility and Basel Medical Group tied by winning 7 of the 14 factors compared between the two stocks.

How does Basel Medical Group compare to NewGenIvf Group?

NewGenIvf Group (NASDAQ:NIVF) and Basel Medical Group (NASDAQ:BMGL) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation.

NewGenIvf Group has a beta of 0.01, suggesting that its stock price is 99% less volatile than the broader market. Comparatively, Basel Medical Group has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market.

NewGenIvf Group has higher earnings, but lower revenue than Basel Medical Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewGenIvf Group	$4.73M	0.73	$9.88M	N/A	N/A
Basel Medical Group	$8.90M	0.94	-$9.50M	N/A	N/A

In the previous week, Basel Medical Group had 2 more articles in the media than NewGenIvf Group. MarketBeat recorded 4 mentions for Basel Medical Group and 2 mentions for NewGenIvf Group. NewGenIvf Group's average media sentiment score of 1.44 beat Basel Medical Group's score of 0.89 indicating that NewGenIvf Group is being referred to more favorably in the media.

Company	Overall Sentiment
NewGenIvf Group	Positive
Basel Medical Group	Positive

66.2% of NewGenIvf Group shares are owned by institutional investors. 31.8% of NewGenIvf Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Company	Net Margins	Return on Equity	Return on Assets
NewGenIvf Group	N/A	N/A	N/A
Basel Medical Group	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewGenIvf Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Basel Medical Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

NewGenIvf Group and Basel Medical Group tied by winning 4 of the 8 factors compared between the two stocks.

Get Basel Medical Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BMGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BMGL vs. The Competition

Export

Metric	Basel Medical Group	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$7.23M	$9.80B	$7.05B	$13.10B
Dividend Yield	N/A	2.55%	2.57%	10.45%
P/E Ratio	N/A	35.17	269.08	25.28
Price / Sales	0.94	4.77	604.11	91.83
Price / Cash	N/A	124.34	70.48	50.90
Price / Book	2.20	3.94	12.91	6.24
Net Income	-$9.50M	$309.96M	$3.45B	$347.60M
7 Day Performance	-4.10%	0.09%	1.11%	1.06%
1 Month Performance	-12.38%	-0.33%	1.33%	0.81%
1 Year Performance	-77.24%	19.52%	62.44%	20.90%

Basel Medical Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BMGL Basel Medical Group	0.9725 of 5 stars	$5.38 +16.5%	N/A	-78.1%	$7.23M	$8.90M	N/A	36	Short Interest Decrease Gap Up High Trading Volume
MGRX Mangoceuticals	0.6665 of 5 stars	$0.49 -6.6%	N/A	-66.2%	$8.45M	$460K	N/A	3	News Coverage Earnings Report Short Interest Increase Gap Down
GXAI Gaxos.ai	1.4087 of 5 stars	$0.85 0.0%	N/A	-24.5%	$6.06M	$3.72M	N/A	3	News Coverage Positive News Earnings Report Analyst Upgrade Short Interest Decrease
AIDX 20/20 Biolabs	2.7768 of 5 stars	$0.46 +0.7%	$5.00 +998.4%	N/A	$5.58M	$1.84M	N/A	14	Earnings Report Short Interest Decrease
IVF INVO Fertility	2.8096 of 5 stars	$1.06 +1.9%	$20.00 +1,786.8%	-98.6%	$2.43M	$7.22M	N/A	10	Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BMGL) was last updated on 8/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Basel Medical Group (BMGL) Competitors

BMGL vs. MGRX, GXAI, AIDX, IVF, and NIVF

How does Basel Medical Group compare to Mangoceuticals?

Summary

How does Basel Medical Group compare to Gaxos.ai?

Summary

How does Basel Medical Group compare to 20/20 Biolabs?

Summary

How does Basel Medical Group compare to INVO Fertility?

Summary

How does Basel Medical Group compare to NewGenIvf Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMGL vs. The Competition

Basel Medical Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Basel Medical Group (BMGL) Competitors

BMGL vs. MGRX, GXAI, AIDX, IVF, and NIVF

How does Basel Medical Group compare to Mangoceuticals?

Do analysts prefer BMGL or MGRX?

Which has more volatility and risk, BMGL or MGRX?

Which has stronger valuation & earnings, BMGL or MGRX?

Does the media favor BMGL or MGRX?

Is BMGL or MGRX more profitable?

Do insiders and institutionals believe in BMGL or MGRX?

Summary

How does Basel Medical Group compare to Gaxos.ai?

Does the media refer more to GXAI or BMGL?

Do institutionals & insiders believe in GXAI or BMGL?

Is GXAI or BMGL more profitable?

Do analysts recommend GXAI or BMGL?

Which has more volatility and risk, GXAI or BMGL?

Which has higher valuation & earnings, GXAI or BMGL?

Summary

How does Basel Medical Group compare to 20/20 Biolabs?

Do analysts recommend AIDX or BMGL?

Does the media favor AIDX or BMGL?

Which has preferable earnings and valuation, AIDX or BMGL?

Is AIDX or BMGL more profitable?

Summary

How does Basel Medical Group compare to INVO Fertility?

Which has more volatility and risk, IVF or BMGL?

Which has stronger valuation and earnings, IVF or BMGL?

Does the media favor IVF or BMGL?

Do analysts recommend IVF or BMGL?

Do insiders & institutionals believe in IVF or BMGL?

Is IVF or BMGL more profitable?

Summary

How does Basel Medical Group compare to NewGenIvf Group?

Which has more risk and volatility, NIVF or BMGL?

Which has higher valuation and earnings, NIVF or BMGL?

Does the media refer more to NIVF or BMGL?

Do institutionals and insiders believe in NIVF or BMGL?

Is NIVF or BMGL more profitable?

Do analysts rate NIVF or BMGL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMGL vs. The Competition

Basel Medical Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools